Trials / Completed
CompletedNCT00327769
Faslodex Advanced Breast Cancer Local Chinese Study
A Double Blind, Double Dummy, Randomised, Multicentre Study to Compare the Efficacy and Safety of Fulvestrant 250mg With Arimidex 1mg as a Secondary-line Therapy in the Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 234 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of Faslodex as secondary-line treatment compared with Arimidex in oestrogen receptor positive postmenopausal advanced breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fulvestrant | 250 mg intramuscular injection |
| DRUG | Anastrozole | 1 mg tablet |
Timeline
- Start date
- 2005-11-01
- Completion
- 2007-09-01
- First posted
- 2006-05-19
- Last updated
- 2011-01-25
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00327769. Inclusion in this directory is not an endorsement.